NCT01349920View on ClinicalTrials.gov

Biomarkers of Intestinal Mucosal Healing in Crohn's Disease (P08143)

CompletedOBSERVATIONAL
Enrollment

15

Participants

Timeline

Start Date

November 28, 2012

Primary Completion Date

September 28, 2015

Study Completion Date

September 28, 2015

Conditions
Crohn Disease
Interventions
DRUG

Infliximab

Infliximab administered intravenously at a dose of 5 mg/kg at study Weeks 0, 2, 6, 14, and 22.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01349920 - Biomarkers of Intestinal Mucosal Healing in Crohn's Disease (P08143) | Biotech Hunter | Biotech Hunter